Home|DSIJArticleDetail

230 per cent returns: This multibagger pharmaceutical company announced approval for a new drug from US FDA; do you own it?
230 per cent returns: This multibagger pharmaceutical company announced approval for a new drug from US FDA; do you own it?

230 per cent returns: This multibagger pharmaceutical company announced approval for a new drug from US FDA; do you own it?

The company has delivered returns of 14.5 per cent over the past 3 years and returns of 230 per cent over the past 5 years.

Siddharth Mane Article rating: 4.1

The company has a ROCE of 19.4 per cent and a ROE of 19.1 per cent.

This innovative Pharma company launches Thiamine Hydrochloride Injection USP in the United States!
This innovative Pharma company launches Thiamine Hydrochloride Injection USP in the United States!

This innovative Pharma company launches Thiamine Hydrochloride Injection USP in the United States!

The company holds a leadership position in cardiovascular, anti-diabetic and respiratory segments and is the third-largest pharmaceutical company in the U.S. by prescriptions.

Siddharth Mane Article rating: 4.0

A global pharmaceutical company, has announced the launch of Thiamine Hydrochloride Injection USP, following the approval of its alliance partner Caplin Steriles Limited's ANDA by the U.S. FDA.

Upper Circuit: This micro-cap pharma stock reported stellar Q3FY23 results!
Upper Circuit: This micro-cap pharma stock reported stellar Q3FY23 results!

Upper Circuit: This micro-cap pharma stock reported stellar Q3FY23 results!

In an aim to expand their product portfolio, the company is focusing on developing multiple manufacturing sites

Bhavya Rathod Article rating: 3.7

They initiated contract manufacturing from three new locations this quarter and with this, they are currently manufacturing at nine locations across India

Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?
Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?

Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?

This stock is currently available at a PE multiple of 21.47 and an ROE of 9.68, all of which indicate good management effectiveness.

Kiran Shroff Article rating: 4.3

This stock is currently available at a PE multiple of 21.47 and an ROE of 9.68, all of which indicate good management effectiveness.

Shilpa Medicare skyrockets by 10.47 per cent on a weak market day!
Shilpa Medicare skyrockets by 10.47 per cent on a weak market day!

Shilpa Medicare skyrockets by 10.47 per cent on a weak market day!

The board of the company also has recommended a dividend of Rs 1.10 per equity share for the financial year ended March 31, 2022.  

Sayali Kotwal Article rating: 5.0

The shares of Shilpa Medicare soared 10.47 per cent to Rs 453.25 on BSE after the company announced promising results for the quarter that ended on March 31, 2022.

DSIJ MINDSHARE

Mkt Commentary26-Apr, 2024

Mindshare26-Apr, 2024

Penny Stocks26-Apr, 2024

Multibaggers26-Apr, 2024

Multibaggers26-Apr, 2024

Knowledge

General26-Apr, 2024

Fundamental21-Apr, 2024

General21-Apr, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Condition | Privacy Statement | WhiteList